Results 251 to 260 of about 59,567 (314)

Practitioner Review: Infant mental health meets cell and molecular biology – a look to the future

Journal of Child Psychology and Psychiatry, Volume 67, Issue 7, Page 1190-1202, July 2026.
Background A major research effort in the past two decades has begun to illuminate how experience ‘gets under the skin’ – that is – the cellular and molecular processes that are associated with adversity and resilience. Methods We selectively review three areas of this research: epigenetics, especially DNA methylation, telomere length, and inflammatory
Charles H. Zeanah, Megan Hare, Katherine Cowhey, Stacy S. Drury   +3 more
wiley   +1 more source

Concept of natural genome reconstruction.Part 5. Analysis of changes in the lifespan of old animals after reinfusion of bone marrow cells derived from old animals and treated with hDNAgr in combination with recombinant human angiogenin. [PDF]

Vavilovskii Zhurnal Genet Selektsii
Ruzanova VS, Grivtsova LU, Oshikhmina SG, Proskurina AS, Ritter GS, Dolgova EV, Kirikovich SS, Levites EV, Efremov YR, Dubatolova TD, Meschaninova MI, Mamaev AL, Taranov OS, Sidorov SV, Leplina OY, Ostanin AA, Chernykh ER, Kolchanov NA, Bryukhovetskiy AS, Bogachev SS.   +19 more
europepmc   +1 more source

The physiology of survival: Space

Experimental Physiology, EarlyView.
Damian M. Bailey, Angelique van Ombergen
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, Volume 20, Issue 6, Page 1398-1419, June 2026.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Determinants of chromosome-specific telomere lengths among 2573 All of Us participants. [PDF]

Nat Commun
Jain N, Luo J, Yang Y, Demanelis K, Ahsan H, Aschebrook-Kilfoy B, Chen LS, Pierce BL.   +7 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, Volume 20, Issue 6, Page 1612-1625, June 2026.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers. [PDF]

Signal Transduct Target Ther
Price JDW, Vizeacoumar FS, Abuhussein O, Maranda V, Zhang Y, Adachi H, Nguyen K, Kyrylenko L, Rangel-Pozzo A, Dong H, Gong L, Materi A, Walke P, Ganapathysamy A, Denomy C, Freywald T, Dahiya R, Elhasasna H, Saxena A, Vizeacoumar JP, Patel H, Rajamanickam K, de Oliveira DM, Lazell-Wright M, Morales AM, Aggarwal A, Xu JL, Alli N, Munhoz EP, Gao P, Salsman J, Dahiya DK, Kola NS, Gonzalez-Lopez C, Thibault P, Levin M, Dellaire G, Jette N, Groot G, Köbel M, Lee CH, Hopkins L, Krishnan A, Ahmed S, Eskiw C, Barakat KH, Thakur A, Wu Y, DePinho RA, Mai S, Yu YT, Wong JMY, Freywald A, Vizeacoumar FJ.   +53 more
europepmc   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, Volume 20, Issue 6, Page 1643-1660, June 2026.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Tissue morphology predicts telomere shortening in human tissues. [PDF]

Cell Rep Methods
Yadav A, Alvarez K, Adeleye A, Wang YX, Jackson M, Sinha S.   +5 more
europepmc   +1 more source